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Summary
Objective: Sepsis is a common condition encountered in hospital environments. There 
is no effective treatment for sepsis, and it remains an important cause of death at inten-
sive care units. This study aimed to discuss some methods that are available in clinics, 
and tests that have been recently developed for the diagnosis of sepsis. Methods: A sys-
tematic review was performed through the analysis of the following descriptors: sepsis, 
diagnostic methods, biological markers, and cytokines. Results: The deleterious effects 
of sepsis are caused by an imbalance between the invasiveness of the pathogen and the 
ability of the host to mount an effective immune response. Consequently, the host’s im-
mune surveillance fails to eliminate the pathogen, allowing it to spread. Moreover, there 
is a pro-inflammatory mediator release, inappropriate activation of the coagulation and 
complement cascades, leading to dysfunction of multiple organs and systems. The dif-
ficulty achieve total recovery of the patient is explainable. There is an increased incidence 
of sepsis worldwide due to factors such as aging population, larger number of surgeries, 
and number of microorganisms resistant to existing antibiotics. Conclusion: The search 
for new diagnostic markers associated with increased risk of sepsis development and 
molecules that can be correlated to certain steps of sepsis is becoming necessary. This 
would allow for earlier diagnosis, facilitate patient prognosis characterization, and pre-
diction of possible evolution of each case. All other markers are regrettably constrained 
to research units.
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IntroductIon
Sepsis, considered the 10th leading cause of death in 
the United States (US), is a challenge for medicine to-
day1-5, and its incidence ranges from 76 to 100 cases per 
100,000 people. Sepsis and septic shock are among the 
major causes of death in non-coronary intensive care 
units (ICU)6-9. In Brazil, the average mortality rate is 
estimated to be of approximately 29%10. In addition, 
sepsis is not a reportable disease. As a consequence, it 
is estimated that these numbers may be higher, since 
the cause of death might be attributed to other compli-
cations. Some studies, for example, have claimed that 
the mortality rate due to sepsis might vary from 30% 
to 60%11. In an evaluation in the US, involving more 
than 6 million hospital records in 7 states, the average 
number of cases of sepsis was 751,000 per year, with a 
mortality rate of 28.6%12. Alarming headlines declare 
that incidence and mortality rates of sepsis are increas-
ing each year. Recently, it was reported that an average 
of 215,000 people a year died from sepsis between 1979 
and 2000 in the US, and an increase of 9% per year of 
mortality rate6. Aging population, multidrug-resistant 
microorganisms, popularization of invasive techniques 
(such as bladder catheters, endotracheal tubes, and in-
travascular catheters), and increasing number of surgi-
cal procedures are among the factors that might explain 
the higher incidence of sepsis. The peak incidence usu-
ally occurs in individuals in the 6th decade. Thus, ge-
netic variation, unconventional lifestyle, and gender are 
some other factors that may increase the risk of sepsis.
Although much is known about sepsis, the disease 
has shown a complex clinical and therapeutic profile. 
Sepsis is a syndrome characterized by a systemic inflam-
mation that can occur in the body as a consequence of a 
simple infection. Sepsis is actually a counteracting ‘mis-
response’ of the body against infecting microorganisms. 
This uncontrolled reaction is characterized by a biased 
system, in favor of pro-inflammatory, pro-coagulant, 
and over reactive immune inflammatory response13. 
The magnitude of the response depends on several 
factors, such as the virulence of the organism, host ge-
netics, and immune status. Moreover, for the progres-
sion of the infection to occur, it is necessary that the 
host cannot contain or destroy the primary infection. 
Thus, most patients develop either sepsis, or the sys-
temic inflammatory response syndrome (SIRS), which 
is a clinical pro-inflammatory response, predominantly 
cytokine-mediated, to a nonspecific insult of either in-
fectious or noninfectious origin. In addition, advances 
in cellular and molecular biology have demonstrated 
that bacterial invasion or its by-products (endotoxins, 
lipopolysaccharide – LPS) need to interact harmfully 
with the host’s immune system for the development of 
sepsis14. Moreover, among patients who develop sepsis, 
only a few progress to severe sepsis and are at a higher 
risk of death15-17. 
In the progress of the uncontrolled inflammatory 
response in sepsis, unpredictable cardiovascular phe-
nomena occur, such as hypovolemia, peripheral vaso-
dilation, myocardial depression, increased endothelial 
permeability, and hypermetabolism. Patients with sepsis 
according to a consensus established at the International 
Conference of Sepsis14 show a diversity of clinical signs. 
Temperatures can vary from higher than 38ºC to lower 
than 36ºC, heart rate may be above 90 beats per min-
ute (bpm), tachypnea (FR > 20/min) or hyperventilation 
(pCO2 <  32 torr) may be present, and white blood cell 
count may be above 12,000 or below 4,000 cells/µL14,18,19. 
Severe sepsis is characterized when there is associa-
tion of sepsis with organ dysfunction. Septic shock, on 
the other hand, occurs when resuscitation maneuvers 
are mandatory due to hypotension or persistent changes 
in tissue perfusion after conservative attempts of hemo-
dynamic homeostasis maintenance are performed. Nev-
ertheless, the boundaries between severe sepsis, septic 
shock, and multiple organ dysfunctions are not clearly 
defined in clinical practice19-21.
Several inflammatory markers have failed to fulfill 
the requirements to be eligible for an early and reli-
able diagnostic predictor of sepsis. Studies17,22 have 
shown that the best policy is to consider a combination 
of markers, since the majority of the studies in animal 
models are not reproducible in humans. This, added 
to the fact that several markers are commonly found 
in a wide range of diseases, creates a great difficulty 
in relating laboratory data to the patients prognosis. 
Clinical laboratory diagnosis is crucial to avoiding de-
lay in treatment23-25. Thus, one-quarter of patients with 
sepsis have inadequate treatment and worse prognosis 
as a consequence of a delayed diagnosis12,17,22. In sum-
mary, diagnosis can be considered a two-sided process. 
Firstly, finding biomarkers capable of monitoring meta-
bolic homeostasis and constantly evaluating patient se-
verity, indicating whether there is systemic or specific 
organ involvement. Secondly, finding a marker related 
to pathogen identification, through a quick screening 
of the patient26. A diagram depicting the diagnostic 
sepsis phases is presented in Figure 1. In other words, 
laboratory tests should aim to identify compromised 
systems or organs, including indicators of inflamma-
tory response in peripheral blood (pro-inflammatory 
mediators and acute phase indicators) and indicators of 
organic disorders. Enhanced serum lactate, cytokines, 
colony stimulating factor, and granulocyte markers of 
inflammation may be early indicators of more severe 
conditions, such as SIRS. 
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methodS
The data presented in this review originated from a sys-
tematic analysis of the PubMed database over the last 10 
years by searching for the following terms: sepsis diag-
nostic, sepsis methods, biological markers, and cytokines. 
The authors have attempted to summarize and to reference 
the literature about sepsis and laboratory diagnostics.
hematologIcal aSSeSSment
Blood count analysis and peripheral blood smear tests 
are usually the first results to be obtained and can pro-
vide important information for the clinical management 
of patients. Frequent leukocytosis is noticeable in patient 
with sepsis. However, leukopenia or pancytopenia may 
also be found27. Neutrophilia with a left shift and the pres-
ence of immature granulocytes with toxic granulations can 
be found. The latter, when present in large numbers, is a 
marker of severity of infection.
Inflammatory mediators cause increased vascular 
permeability and immune cells chemotaxis to the site28-33. 
In this process, neutrophils move out of the capillaries, 
enter the tissues, releasing proteolytic enzymes and reac-
tive oxygen species33-35. Platelets are then attracted to and 
stick to the damaged endothelium. Platelets and leuko-
cytes occlude the microvasculature leading to a decrease 
in the blood flow. Following, there is a need to increase 
oxygen offered to tissues, but this is impossible due to 
vascular changes.
In addition, there is activation of the coagulation cas-
cade secondary to the complement system, causing a re-
duction of anticoagulants factors13. In patients with mi-
crovascular coagulopathy, it is possible to find different 
degrees of thrombocytopenia and microangiopathy, with 
or without the presence of erythroblasts, and schizocytes36. 
Thrombocytopenia is an independent prognostic marker 
of mortality in sepsis and should be carefully investi-
gated. The course of sepsis may be the result of drug use, 
post-transfusion purpura, thrombotic thrombocytopenic 
purpura, disseminated intravascular coagulation, or hep-
arin-induced thrombocytopenia37. Thus, these candidates 
for diagnostic markers should be intensively investigated 
in the near future.
 
BIochemIcal aSSeSSment
In sepsis there is a great variation of the patient’s elec-
trolytes levels and elevated levels of liver enzymes due to 
hypoxia. There is also a pronounced hyperglycemia with 
a hyper- or hypocoagulable state, and metabolic acidosis 
with respiratory compensation and increased anion gap 
due to lactic acid production are commonly found38.
The use of biochemical diagnostic markers is vi-
tal to determine the prognosis of the patient. The use 
of gas analysis and other tests such as lactate, albumin, 
C-reactive protein (PCR), alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and hemopex-
in levels are important not only to indicate patient status, 
but also to give a good picture of the changes in blood 
homeostasis20,39-41. Gas analysis also provides important 
information regarding the patient’s need for fluid replace-
ment, since the presence of elevated PCR, ALT, and AST 
is relatively common in sepsis. This may be due to liver 
injury, post-ischemic condition, and it might also indicate 
drug toxicity, or be a synonym of direct aggression of the 
hepatocytes with mitochondrial dysfunction20. Lactate 
levels, for which tests are available in most hospitals and 
are relatively low cost, appear to be associated with in-
creased mortality risk in sepsis42.
Albumin is an independent diagnostic marker of se-
verity and mortality in sepsis. During inflammation, there 
is a leakage of serum albumin to the interstitium and al-
buminuria in varying degrees. The claimed replacement 
of exogenous albumin remains controversial in terms of 
mortality reduction43. The albumin role is better estab-
lished in patients with liver dysfunction, ascites, and acute 
lung injury43. Natriuretic peptides (NP) are released by 
atrial distension and play important role in regulating 
blood volume, and are considered markers of heart failure. 
In patients with septic shock, increased levels of NP are as-
sociated with higher mortality by myocardial-depression. 
Recent studies with ICU patients demonstrated that NP 
levels were significantly higher in survivors than in non-
survivors, therefore they are a potential indicator of posi-
tive prognosis in sepsis44-48.
Blood lactate levels can also be useful in evaluating 
severe sepsis49-50. Serum lactate is a good indicator of the 
presence of hypoxic tissue during septic shock, since its 
production takes place during anaerobic metabolism51. 
Research conducted by Arnold et al.51 and Nguyen et al.52 
provided results suggesting that the clearance lactate rate 
measure is important in order to identify patients who 
Figure 1 – Diagnostic sepsis phases.
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better respond to treatment and have a more favorable 
prognosis. In addition, serial measurements of lactate lev-
els in septic patients are more appropriate to assess dis-
ease progression rather than a single measurement51. The 
determination of plasma procalcitonin (PCT) can also be 
valuable in early diagnosis of patients with severe sepsis53. 
PCT is the precursor of calcitonin, and higher levels are 
associated with the development of severe sepsis. Com-
monly, there is an elevation of PCT levels 4 h after the on-
set of symptoms, peaking between 8 h and 24 h54. There is 
evidence that PCT levels are higher in infections caused by 
Gram-negative than those caused by Gram-positive bacte-
ria55 and it seems to be more specific than PCR18,56.
 Ferritin, serum iron binding capacity, and transferrin 
are tests that must be interpreted with caution in septic 
patients, since all may be changed due to the presence of 
high levels of hepcidin57. Ferritin is an acute phase protein 
that is usually elevated in sepsis and reflects the status of 
iron stores. The authors of the present study proposed that 
the level of soluble transferrin receptor should be a good 
assessment of iron store levels, but even this test has its 
accuracy reduced in cases of sepsis. The interpretation of 
these tests should be performed in conjunction with the 
level of hemoglobin and reticulocytes. Another interest-
ing test reported is insulin sensitivity test58-61. According 
to Lin et al., glycemic sensitivity reflects the physiological 
state of the patient together with temperature, heart rate, 
breathing score, and blood pressure. Careful studies on the 
changes of these rates would allow physicians to elaborate 
a mathematical model to predict the onset of sepsis and 
the need for antibiotics58,62.
 
mIcroBIologIcal evaluatIon
Despite numerous advances in the diagnosis of sepsis, the 
microbiological evaluation has not yet lost its importance, 
since it is paramount to identify the causative agent in or-
der to choose an adequate antibiotic therapy. Microbio-
logical evaluation includes direct tests and blood (at least 
two) or other body fluid culture such as urine, cerebrospi-
nal fluid, feces, secretions, and exudates62,63. Preferably, the 
sample collection should be performed before the use of 
antimicrobial therapies. For hospitalized patients, material 
for culture can also be collected through other methods, 
including venous or arterial catheters (blood catheters), 
urinary catheter, tracheotomy (tracheal aspirate), and 
sutures or scars from recent surgeries62. Although blood 
culture is the currently adopted method, several patients 
with sepsis have negative results for this exam. In the 
ICU, the main causative agents of sepsis are Staphylococ-
cus spp., Staphylococcus aureus, Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, 
Enterococcus faecalis, Acinetobacter baumannii, and Can-
dida spp.64,65. The use of automated systems for monitoring 
blood cultures (VITEK, ESP Culture Trek Diagnostic Sys-
tems; BacT / Alert and BACTEC the bioMérieux BD) in-
creases the speed and improves their efficiency63,64. Most 
systems monitor the consumption of carbon dioxide 
(CO2) by colorimetric methods, generally detecting posi-
tivity after 48 hours. An important point to highlight is the 
way in which the sample collection is performed, in order 
to avoid false positives and contamination with skin flora.
 
Immune aSSeSSment
During an immune response, there is activation of vari-
ous mechanisms of host defense against a pathogen, such 
as inflammation, complement and coagulation cascades, 
polymorfonuclear (PMN) activation, and chemoattrac-
tion to the site13,27. These processes are over reactive in 
SIRS condition. This exacerbated activation of the inflam-
matory response may lead to greater cell damage, which 
can culminate with an impairment of the immune re-
sponse. Despite the fact that only a few tests are commer-
cially available for clinical evaluation purposes, there are 
several other inflammatory mediators that are screened 
in the experimental field. Among those markers used as 
mediators in sepsis there are cytokines such as tumor ne-
crosis factor alpha (TNF)-α, interleukin (IL) -1, IL-6, IL-8, 
IL-10, and interferon (IFN)-γ66-69, and the presence of 
bacterial products in the blood or the bacterium itself70-71. 
IL-1 and TNF-α cytokines are the first cytokines released 
in an infection and stimulate cellular response. These cy-
tokines release secondary mediators, resulting in chemo-
taxis and granulocyte activation28,33. These, in turn, lead 
to another round of cytokine outbreak, which could also 
give a good picture of the inflammatory process if they 
could be assessed.
A good example of an acute mediator is IL-6, which 
is also a predictor of the severity and prognosis of sepsis. 
Nonetheless, this cytokine lacks specificity, since is likely 
to be present in high levels in several other inflammatory 
processes60,72-74. For the same reason, TNF-α cannot be 
used for the diagnosis of sepsis. IL-10 is an anti-inflamma-
tory cytokine and its level appears to indicate whether the 
patient is able to respond to an aggression. Bacteria and 
their by-products, such as LPS and lipoprotein binding 
protein (LBP), are also good inflammation markers. LBP is 
an acute phase protein involved in immune response me-
diated by endotoxin that allows the endotoxin to bind to 
CD14 receptor, which subsequently activates the expres-
sion of toll-like receptors (TLR)-2 and TLR-4 and triggers 
gene transcription75. 
Unfortunately, all these markers are common to many 
different inflammation types and are also found in simple 
infections, and thus, are not good predictors of inflamma-
tion severity. Also, it is necessary to process the sample im-
mediately, because these proteins are labile and can easily 
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change or be degraded. Once again, as previously men-
tioned, it is imperative to find a “pathognomonic” marker 
for sepsis that can routinely be used for clinical diagnosis.
 
molecular dIagnoSIS
The use of molecular biology techniques to diagnose new 
cases of sepsis is necessary. This has been strongly en-
couraged by the requirement of smaller samples, capable 
of providing reliable results and earlier diagnosis. These 
techniques can detect the presence of LPS in the blood, 
expression of High-Mobility Group Box (HMGB) -1 or 
even identify bacterial DNA76. These tests, however, are 
not 100% accurate, but they do strongly indicate the pres-
ence of sepsis. Detection of bacterial DNA fragments by 
real-time polymerase chain reaction (RT-PCR) in blood 
samples, or 16S rRNA fragments of Gram-positive and 
Gram-negative bacteria and Candida in the 18S rRNA 
might be very promising to help early detection of sepsis, 
since they have shown a high degree of specificity and sen-
sitivity. The main disadvantages of these techniques are the 
high costs, the lack of standardization, and the need for 
skilled personnel to perform them.
The ideal test should be precise, affordable, reproduc-
ible, fast, and show high specificity and sensibility, being 
able to accurately evaluate the patient during different 
stages of the condition. Until now, none of the tests ful-
filled these conditions. 
 
ScorIng predISpoSItIon to SepSIS
The criteria for diagnosis of sepsis was established in 1991, 
and revised only at the International Sepsis Definitions 
Conference in 200137. The risk and individual symptoms 
during sepsis were defined as PIRO: predisposition to in-
fection and response to organ dysfunction37,77. This score 
is important to establish a correct and personalized treat-
ment implementation in sepsis. The PIRO score uses sev-
eral indicators such as prior co-morbidities, gender, age, 
culture and characterization of the sensitivity of the mi-
croorganism, SIRS, manifestations of sepsis, shock, PCR, 
and failure rate of organ dysfunction37. Another widely 
used diagnostic criterion is the age acute physiology and 
chronic health examination (APACHE)78-79, but it is more 
restricted and sometimes fails to differentiate sepsis from 
SIRS. In addition, the information obtained from the 
monitoring of indicators of severity (sepsis-related organ 
failure assessment – SOFA) may be more appropriate in 
many cases80.
  
concluSIon
Rapid diagnosis is essential in the case of sepsis. Labora-
tory findings are important and represent a two-sided pro-
cess. The first side is responsible for monitoring changes in 
metabolic homeostasis and patient evaluation; indicating 
severity of the disease and whether there is involvement 
of specific organs or entire systems. The second refers to 
pathogen identification through a microbiological screen-
ing of the patient.
Several indicators might be used for this purpose: 
pro-inflammatory mediators, acute phase indicators, and 
pathogen metabolites. Lactate levels, serum cytokines, 
presence of colony stimulating factors, and plasma nitric 
oxide levels may be early indicators of SIRS, but remain 
restricted to research units. 
An ideal test should allow for a fast and precise diagno-
sis, be reproducible, affordable, and have high sensitivity 
and specificity. Despite several candidates such as blood 
culture, serum lactate, and PCT levels, a combination of 
tests is still compulsory for the diagnosis of sepsis. In a 
field where speed and accuracy are needed, a gold stan-
dard test for sepsis is still searched for. Because health is 
so precious, knowledge must rise to meet current needs.
 
acknowledgementS
The authors apologize to the many researchers whose 
work they have not been able to discuss in this limited re-
view. Joilson Oliveira Martins is supported by Fundação 
de Amparo à Pesquisa do Estado de São Paulo (FAPESP), 
Conselho Nacional de Desenvolvimento Científico e Tec-
nológico (CNPq, Projeto Universal), and Pró-reitoria de 
Pesquisa da Universidade de São Paulo (Projeto I and No-
vos Docentes), Brazil.
referenceS
1. Suffredini AF, Munford RS. Novel therapies for septic shock over the past 4 
decades. JAMA. 2011;306:194-9. 
2. Mangia CM, Kissoon N, Branchini OA, Andrade MC, Kopelman BI, Carcillo J. 
Bacterial sepsis in Brazilian children: a trend analysis from 1992 to 2006. PLoS 
One. 2011;6:e14817.
3. Booker E. Sepsis, severe sepsis, and septic shock: current evidence for emer-
gency department management. Emerg Med Pract. 2011;13:1-22.
4. Hecksher CA, Lacerda HR, Maciel MA. Characteristics and outcomes of pa-
tients treated with drotrecogin alpha and other interventions of the “surviving 
sepsis” campaign in clinical practice. Rev Bras Ter Intensive. 2008;20:135-43.
5. Pizzolatti ML, Moritz RD, Andrade J. Analysis of knowledge among emer-
gency medicine physicians about systemic inflammatory responses syndrome 
(SIRS), sepsis, severe sepsis and septic shock definitions criteria. Rev Bras Ter 
Intensive. 2004;16:210-4.
6. Schefold JC, Hasper D, Jörres A. Organ crosstalk in critically ill patients: he-
mofiltration and immunomodulation in sepsis. Blood Purif. 2009;28:116-23. 
7. Sales-Júnior JAL, David CM, Hatum R, Souza PCSP, Japiassú A, Pinheiro CTS, 
et al. An epidemiological study of sepsis in intensive care units. Sepsis Brazil 
Study. Rev Bras Ter Intensive. 2006;18:9-17.
8. Rosolem MM, Rabello LS, Lisboa T, Caruso P, Costa RT, Leal JV, et al. Criti-
cally ill patients with cancer and sepsis: clinical course and prognostic factors. 
J Crit Care. 2012;27(3):301-7.
9. Salluh JI, Rabello LS, Rosolem MM, Soares M, Bozza FA, Verdeal JC, et al. The 
impact of coagulation parameters on the outcomes of patiet alents with severe 
community-acquired pneumonia requiring intensive care unit admission. J 
Crit Care. 2011;26:496-501.
10. Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M, et 
al. Brazilian Sepsis Epidemiological Study. Brazilian Sepsis Epidemiological 
Study (BASES study). Crit Care. 2004; 8:R251-R26060.
11. Lin J, Lee DS, Chase JG, Hann CE, Lotz T, Wong XW. Stochastic modelling of 
insulin sensitivity variability in critical care. Biomedical Signal Processing & 
Control. 2006;1:229-42.
12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 
Epidemiology of severe sepsis in the United States: analysis of incidence, out-
come, and associated costs of care. Crit Care Med. 2001;29:1303-10.
Diagnostic methoDs in sepsis: the neeD of speeD
503Rev Assoc Med Bras 2012; 58(4):498-504
13. Villar J, Flores C, Perez-Mendez L. Genetic determinants of survival in sepsis 
and acute lung injury. Minerva Anestesiol. 2008;74:341-5.
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Con-
ference: definition for sepsis and organ failure and guidelines for the use for 
innovative therapies in sepsis. Chest. 1992;101:1644-1655.
15. Kellum JA, Angus DC. Genetic variation and risk of sepsis. Minerva Aneste-
siol. 2003;69:245-53.
16. Elias AC, Matsuo T, Grion CM, Cardoso LT, Verri PH. Incidence and risk fac-
tors for sepsis in surgical patients: a cohort study. J Crit Care. 2012;27(2):159-66.
17. Shiramizo SC, Marra AR, Durão MS, Paes ÂT, Edmond MB, Pavão dos Santos 
OF. Decreasing mortality in severe sepsis and septic shock patients by imple-
menting a sepsis bundle in a hospital setting. PLoS One. 2011;6:e26790.
18. Dahaba AA, Metzler H. Procalcitonins role in the sepsis cascade. Is procalcito-
nin a sepsis marker or mediator? Minerva Anestesiol. 2009;75:447-52.
19. Katz DV, Troster EJ, Vaz FA. Dopamine and kidney in sepsis: a systematic re-
view. Rev Assoc Med Bras. 2003;49:317-25.
20. Carvalho PRA, Trotta EA. Avanços no diagnóstico e tratamento da sepse. 
J Pediatr. 2003;79:S195-S204.
21. Salles MJ, Sprovieri SR, Bedrikow R, Pereira AC, Cardenuto SL, Azevedo PR, 
et al. Systemic inflammatory response syndrome/sepsis - review and terminol-
ogy and physiopathology study. Rev Assoc Med Bras. 1999;45:86-92.
22. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. 
Clin Chest Med. 2008;29:591-603. 
23. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endo-
thelial activation in sepsis - a systematic review. Crit Care. 2012;16:R7.
24. Chew MS, Ihrman L, During J, Bergenzaun L, Ersson A, Unden J, et al. Extra-
vascular lung water index improves the diagnostic accuracy of lung injury in 
patients with shock. Crit Care. 2012;16:R1.
25. Angus DC. The search for effective therapy for sepsis: back to the drawing 
board? JAMA. 2011;306:2614-5.
26. Becker JU, Theodosis C, Jacob ST, Wira CR, Groce NE. Surviving sepsis in low-
income and middle-income countries: new directions for care and research. 
Lancet Infect Dis. 2009;9:577-82.
27. Jacobi J. Pathophysiology of sepsis. Am J Health Syst Pharm. 2002;15:S3-8.
28. Oliveira C, Xavier RA, Anjos-Vallota E, Martins JO, Silveira VL, Gonçalves 
LR, et al. Effect of plant neutrophil elastase inhibitor on cell migration, ad-
hesion and cytokine release on inflammatory conditions. Br J Pharmacol. 
2010;161:899-910.
29. Oliveira WR, Cavassani SS, Maganhin CC, Carbonel AA, Simões MJ, Simões 
RS, et al. Histomorphologic and respiratory aspects of acute lung injury in rats 
induced by experimental sepsis and under pentoxifylline treatment. Rev Assoc 
Med Bras. 2009;55:127-31.
30. Costantini TW, Deree J, Martins JO, Loomis W, Bansal V, Coimbra R. A novel 
fluid resuscitation strategy modulates pulmonary transcription factor activa-
tion after hemorrhagic shock. Clinics. 2010;65:621-8.
31. Sunahara KK, Martins JO. Alveolar macrophages in diabetes: friends or foes? 
J Leukoc Biol. 2012;91(6):871-6.
32. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, et al. Sur-
vival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 
2012;40:43-9.
33. Alba-Loureiro TC, Munhoz CD, Martins JO, Cerchiaro GA, Scavone C, 
Curi R, et al. Neutrophil function and metabolism in individuals with diabetes 
mellitus. Braz J Med Biol Res. 2007;40:1037-44.
34. Sunahara KKS, Sannomiya P, Martins JO. Briefs on insulin and innate immune 
response. Cell Physiol Biochem. 2012;29(1-2):1-8.
35. Souza YM, Fontes B, Martins JO, Sannomiya P, Brito GS, Younes RN, et al. 
Evaluation of the effects of ozone therapy in the treatment of intra-abdominal 
infection in rats. Clinics. 2010;65:195-202.
36. De Backer D, Donadello K, Taccone FS, Ospina-Tascon G, Salgado D, Vincent 
JL. Microcirculatory alterations: potential mechanisms and implications for 
therapy. Ann Intensive Care. 2011;1:27.
37. Wang Z, Yu Z, Su J, Cao L, Zhao X, Ruan C. Sepsis-induced disseminated in-
travascular coagulation with features of thrombotic thrombocytopenic pur-
pura: a fatal fulminant syndrome. Clin Appl Thromb Hemost. 2011;17:251-3.
38. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. For 
the International Sepsis Definitions Conference. 2001 SCCM/ESICM/
ACCP/ATS/ SIS International Sepsis Definitions Conference. Crit Care Med. 
2003;31:1250-6
39. Claessens YE, Schmidt J, Batard E, Grabar S, Jegou D, Hausfater P, et al. Can 
C-reactive protein, procalcitonin and mid-regional pro-atrial natriuretic 
peptide measurements guide choice of in-patient or out-patient care in acute 
pyelonephritis? Biomarkers In Sepsis (BIS) multicentre study. Clin Microbiol 
Infect. 2010;16:753-60.
40. Ceccon ME, Vaz FA, Diniz EM, Okay TS. Interleukins 6 and C-reactive protein 
for the diagnosis of late onset sepsis in the newborn infant. Rev Assoc Med 
Bras. 2006;52:79-85.
41. Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infec-
tions. ScientificWorldJournal. 2010;10:1941-6.
42. Karon B, Scott R, Burritt M, Santrach P. Comparison of lactate values between 
point-of-care and central laboratory analyzers. Am J Clin Pathol. 2007;128: 
168-71.
43. Han J, Martin GS. Does albumin fluid resuscitation in sepsis save lives? 
Crit Care Med. 2011;39:418-9.
44. Rudiger A, Gasser S, Fischler M, Hornemann T, Von Eckardstein A, Mag-
giorini M. Comparable increase of B-type natriuretic peptide and amino-
terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, 
septic shock, and acute heart failure. Crit Care Med. 2006;34:2140-4.
45. Guinard-Barbier S, Grabar S, Chenevier-Gobeaux C, Quinquis L, Schmidt J, 
Kierzek G, et al. Is mid-regional pro-atrial natriuretic peptide (MRproANP) 
an accurate marker of bacteremia in pyelonephritis? Biomarkers. 
2011;16:355-63.
46. Iapichino G, Marzorati S, Umbrello M, Baccalini R, Barassi A, Cainarca M, 
et al. Daily monitoring of biomarkers of sepsis in complicated long-term 
ICU-patients: can it support treatment decisions? Minerva Anestesiol. 
2010;76:814-23.
47. Claessens YE, Mathevon T, Kierzek G, Grabar S, Jegou D, Batard E, et al. 
Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial 
natriuretic peptide to guide site of care of community-acquired pneumonia. 
Intensive Care Med. 2010;36:799-809.
48. Nguyen HB, Van Ginkel C, Batech M, Banta J, Corbett SW. Comparison 
of predisposition, insult/infection, response, and organ dysfunction, acute 
physiology and chronic health evaluation ii, and mortality in emergency de-
partment sepsis in patients meeting criteria for early goal-directed therapy 
and the severe sepsis resuscitation bundle. J Crit Care. 2011;Oct25. [Epub 
ahead of print]
49. Friedman G, Berlot G, Kahn RJ, Vincent JL. Combined measurements of 
blood lactate concentrations and gastric intramucosal pH in patients with 
severe sepsis. Crit Care Med. 1995;23:1184-93.
50. Hajjar LA, Nakamura RE, de Almeida JP, Fukushima JT, Hoff PM, Vincent 
JL, et al. Lactate and base deficit are predictors of mortality in critically ill 
patients with cancer. Clinics. 2011;66:2037-42.
51. Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, et al. Emer-
gency Medicine Shock Research Network Investigators. Multicenter study of 
early lactate clearance as a determinant of survival in patients with presumed 
sepsis. Shock. 2009;32:35-9.
52. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin AM, Ressler J, et al. 
Early lactate clearance is associated with improved outcome in severe sepsis 
and septic shock. Crit Care Med. 2004;32:1637-42.
53. Simon L, Saint-Louis P, Amre DK, Lacroix J, Gauvin F. Procalcitonin and 
C-reactive protein as markers of bacterial infection in critically ill children at 
onset of systemic inflammatory response syndrome. Pediatr Crit Care Med. 
2008;9:407-13.
54. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis 
in critical care. J Antimicrob Chemother. 2011;66:1133-40.
55. Charles PE, Ladoire S, Aho S. et al. Serum procalcitonin elevation in criti-
cally ill patients at the onset of bacteremia caused by either Gram-negative 
or Gram-positive bacteria. BMC Infect Dis. 2008;8:38.
56. Ferreira AM, Sakr Y. Organ dysfunction: general approach, epidemiology, 
and organ failure scores. Semin Respir Crit Care Med. 2011;32:543-51.
57. Bullen J, Griffiths E, Rogers H, Ward G. Sepsis: the critical role of iron. Mi-
crobes Infect. 2000;2:409-15. 
58. Lin J, Parente JD, Chase JG, Shaw GM, Blakemore AJ, Lecompte AJ, et al. 
Development of a model-based clinical sepsis biomarker for critically ill pa-
tients. Comput Methods Programs Biomed. 2011;102:149-55.
59. De Oliveira Martins J, Meyer-Pflug AR, Alba-Loureiro TC, Melbostad H, 
Costa da Cruz JW, Coimbra R, et al. Modulation of lipopolysaccharide-in-
duced acute lung inflammation: Role of insulin. Shock. 2006;25:260-6.
60. Martins JO, Ferracini M, Anger DB, Martins DO, Ribeiro-Jr LF, Sannomiya 
P, et al. Signaling pathways and mediators in LPS-induced lung inflammation 
in diabetic rats: role of insulin. Shock. 2009;31:404-9.
61. Martins JO, Ferracini M, Anger DB, Martins DO, Ribeiro-Jr LF, Sannomiya 
P, et al. Signaling pathways and mediators in LPS-induced lung inflammation 
in diabetic rats: role of insulin. Shock. 2010;33:76-82.
62. Mackenzie I, Lever A. Management of sepsis. BMJ. 2007;335:929-32.
63. Riedel S, Carroll KC. Blood cultures: key elements for best practices and fu-
ture directions. J Infect Chemother. 2010;16:301-16.
64. Molina JM, Cordoba J, Ramirez P, Gobernado M. Deteccion automatica de 
bacterias y hongos en sangre. Enferm Infecc Microbiol Clin. 2008;26:75-80.
65. Ferreira LE, Dalposso K, Hackbarth BB, Gonçalves AR, Westphal GA, Fran-
ça PHC, et al. Molecular panel for detection of sepsis-related microorgan-
isms. Rev Bras Ter Intensiva. 2011;23:36-40.
66. Deree J, Martins JO, Melbostad H, Putnam JG, de Campos T, Hoyt DB, et 
al. Insights into the regulation of TNF-α production in human mononu-
clear cells: the effects of non-specific phosphodiesterase inhibition. Clinics. 
2008;63:321-8.
67. Anjos-Valotta EA, Martins JO, Oliveira MA, Casolari DA, Britto LR, 
Tostes RC, et al. Inhibition of tumor necrosis factor-alpha-induced intercel-
lular adhesion molecule-1 expression in diabetic rats: role of insulin. In-
flamm Res. 2006;55:16-22.
68. Martins JO, Ferracini M, Ravanelli N, Landgraf RG, Jancar S. Insulin inhibits 
LPS-induced signaling pathways in alveolar macrophages. Cell Physiol Bio-
chem. 2008;21:297-304.
Fernando rodrigues Coelho et al.
504 Rev Assoc Med Bras 2012; 58(4):498-504
69. Martins JO, Ferracini M, Ravanelli N, Landgraf RG, Jancar S. Insulin sup-
presses LPS-induced iNOS and COX-2 expression and NF-kappaB activation 
in alveolar macrophages. Cell Physiol Biochem. 2008;22:279-86.
70. Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699-713.
71. Schuerholz T, Marx G. Management of sepsis. Minerva Anestesiol. 
2008;74:181-95. 
72. Martins JO, Wittlin BM, Anger DBC, Martins DO, Sannomiya P, Jancar S. 
Early phase of allergic airway inflammation in diabetic rats: role of insulin on 
the signaling pathways and mediators. Cell Physiol Biochem. 2010;26:739-48.
73. Rosário AL, Park M, Brunialti MK, Mendes M, Rapozo M, Fernandes D, et 
al. SvO(2)-guided resuscitation for experimental septic shock: effects of fluid 
infusion and dobutamine on hemodynamics, inflammatory response, and car-
diovascular oxidative stress. Shock. 2011;36:604-12.
74. Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sep-
sis and the understanding of key immunologic defects. Anesthesiology. 
2011;115:1349-62.
75. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR. High con-
centrations of lipopolysaccharide-binding protein in serum of patients with 
severe sepsis or septic shock inhibit the lipopolysaccharide response in human 
monocytes. Blood. 2001;98:3800-8.
76. Rubulotta F, Marshall JC, Ramsay G, Nelson D, Levy M, Williams M. Predis-
position, insult/infection, response, and organ dysfunction: a new model for 
staging severe sepsis. Crit Care Med. 2009;37:1329-35.
77. Westh H, Lisby G, Breysse F, Böddinghaus B, Chomarat M, Gant V, et al. Multi-
plex real-time PCR and blood culture for identification of bloodstream patho-
gens in patients with suspected sepsis. Clin Microbiol Infect. 2005;15:544-51. 
78. Couto DO, Peixoto-Júnior AA, Farias JLM, Sales DB, Lima JPA, Rodrigues RS, 
et al. Gender and mortality in sepsis: do sex hormones impact the outcome? 
Rev Bras Ter Intensiva. 2011;23:297-303.
79. Siqueira-Batista R, Gomes AP, Calixto-Lima L, Vitorino RR, Perez MCA, 
Mendonça EG, et al. Sepsis: an update. Rev Bras Ter Intensiva. 2011;23:207-16.
80. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. 
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ 
dysfunction/failure. On behalf of the Working Group on Sepsis-Related Prob-
lems of the European Society of Intensive Care Medicine. Intensive Care Med. 
1996;22:707-10.
